Table 3 Target coverage comparison
From: Feasibility of constant dose rate VMAT in the treatment of nasopharyngeal cancer patients
CDR-VMAT | VDR-VMAT | MCO-VMAT | p | |
|---|---|---|---|---|
PTV-GTV | ||||
Dmean (Gy) | 68.41 ± 1.21 | 68.71 ± 1.28 | 68.34 ± 0.47 | 0.42 |
Dmax (Gy) | 71.02 ± 0.93 | 70.66 ± 1.29 | 70.44 ± 0.63 | 0.55 |
V93 (%) | 99.91 ± 0.18 | 99.93 ± 0.04 | 99.98 ± 0.02 | 0.31 |
V95 (%) | 99.72 ± 0.38 | 99.69 ± 0.13 | 99.83 ± 0.16 | 0.38 |
HI | 0.11 ± 0.021 | 0.12 ± 0.016 | 0.11 ± 0.026 | 0.33 |
CI | 0.62 ± 0.64 | 0.57 ± 0.10 | 0.65 ± 0.06 | 0.43 |
CN | 0.62 ± 0.44 | 0.56 ± 0.11 | 0.63 ± 0.05 | 0.26 |
PTV-CTV | ||||
Dmean (Gy) | 56.65 ± 0.47 | 57.50 ± 1.08 | 56.15 ± 0.62 | 1.13 |
Dmax (Gy) | 70.09 ± 0.83 | 70.76 ± 1.06 | 70.57 ± 0.43 | 0.62 |
V93 (%) | 98.74 ± 0.31 | 99.76 ± 0.16 | 99.38 ± 0.43 | 0.01 |
V95 (%) | 98.40 ± 0.48 | 99.53 ± 0.28 | 99.07 ± 0.52 | 0.04 |
HI | 0.28 ± 0.017 | 0.29 ± 0.012 | 0.31 ± 0.023 | 0.01 |
CI | 0.58 ± 0.14 | 0.57 ± 0.10 | 0.60 ± 0.06 | 0.06 |
CN | 0.58 ± 0.04 | 0.56 ± 0.12 | 0.57 ± 0.15 | 0.12 |